Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Cardiac hypertrophy: the good, the bad, and the ugly.

Frey N, Olson EN.

Annu Rev Physiol. 2003;65:45-79. Epub 2003 Jan 9. Review.

PMID:
12524460
2.

Myocyte hypertrophy and apoptosis: a balancing act.

van Empel VP, De Windt LJ.

Cardiovasc Res. 2004 Aug 15;63(3):487-99. Review.

PMID:
15276474
3.

Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death.

Kang YJ.

Toxicol Pathol. 2006;34(1):58-66. Review.

PMID:
16507545
4.
5.

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA.

Circulation. 2002 Jan 1;105(1):85-92.

6.

The renin-angiotensin system and experimental heart failure.

Wollert KC, Drexler H.

Cardiovasc Res. 1999 Sep;43(4):838-49. Review.

PMID:
10615411
7.

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.

Sala V, Gallo S, Leo C, Gatti S, Gelb BD, Crepaldi T.

Mol Med. 2012 Sep 7;18:938-47. doi: 10.2119/molmed.2011.00512. Review.

8.

Novel molecular targets in the treatment of cardiac hypertrophy.

Luedde M, Katus HA, Frey N.

Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):1-20. Review.

PMID:
18221071
9.

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD.

Circ Res. 2004 Jan 9;94(1):110-8. Epub 2003 Dec 1.

10.

Time-warped comparison of gene expression in adaptive and maladaptive cardiac hypertrophy.

Sheehy SP, Huang S, Parker KK.

Circ Cardiovasc Genet. 2009 Apr;2(2):116-24. doi: 10.1161/CIRCGENETICS.108.806935. Epub 2009 Feb 18.

11.
12.
13.

The PTHrP/PTH.1-R bioregulation system in cardiac hypertrophy: possible therapeutic implications.

Halapas A, Diamanti-Kandarakis E, Kremastinos D, Koutsilieris M.

In Vivo. 2006 Nov-Dec;20(6B):837-44. Review.

14.

Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium.

Weber KT, Clark WA, Janicki JS, Shroff SG.

J Cardiovasc Pharmacol. 1987;10 Suppl 6:S37-50. Review.

PMID:
2485029
15.
16.

Mechanotransduction in cardiac hypertrophy and failure.

Lyon RC, Zanella F, Omens JH, Sheikh F.

Circ Res. 2015 Apr 10;116(8):1462-1476. doi: 10.1161/CIRCRESAHA.116.304937. Review.

17.

Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease.

Mirtschink P, Krek W.

Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1822-8. doi: 10.1016/j.bbamcr.2016.02.011. Epub 2016 Feb 16. Review.

18.

Exercise-induced cardiac hypertrophy: a substrate for sudden death in athletes?

Hart G.

Exp Physiol. 2003 Sep;88(5):639-44. Review.

PMID:
12955164
19.

The mechanism of the heart's adaption to prolonged load and dynamics of RNA synthesis in the myocardium.

Meerson FZ, Javitz MP, Breger AM, Lerman MI.

Basic Res Cardiol. 1974 Sep-Oct;69(5):484-99. No abstract available.

PMID:
4280903
20.

Cytoplasmic signaling pathways that regulate cardiac hypertrophy.

Molkentin JD, Dorn GW 2nd.

Annu Rev Physiol. 2001;63:391-426. Review.

PMID:
11181961

Supplemental Content

Support Center